Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (201)

« Back to Publications

Cellular immunity to Streptococcus pneumoniae: implications for vaccine-mediated prevention.

VanSeggelen H. et al, (2026), Expert Rev Vaccines, 25

High respiratory syncytial virus burden in children under 3 years of age across all care levels in England.

Carter EC. et al, (2026), BMJ Open Respir Res, 13

Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine.

Kelleher K. et al, (2026), BMJ Open, 16

Host-microbial interactions at the nasal mucosa in young children and adults: A retrospective, cross-sectional study.

Reiné J. et al, (2026), Cell Rep, 45

Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage at 1-year post-vaccination on rechallenge with Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a controlled human infection study and longitudinal follow-up of a randomised controlled trial.

Chirwa AE. et al, (2026), Lancet Microbe, 7

Disease-Attenuated Pneumococcal Biosynthesis Gene Mutants Invade the Mucosal Epithelium and Induce Innate Immunity.

Weight CM. et al, (2026), J Infect Dis

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Cheliotis KS. et al, (2026), Vaccine, 75

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Tembo G. et al, (2026), Vaccine, 75

Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection.

van Beek LF. et al, (2026), J Infect, 92

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe, 7

Pneumococcal colonisation and mucosal immunity in adults with asthma following experimental human challenge

Reiné J. et al, (2026), BMJ Immunology, 1, e000012 - e000012

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Kudowa E. et al, (2026), NPJ Vaccines

Kinetic profile and mucosal capsular polysaccharide IgG responses to serotype 3 pneumococcus in the adult oropharynx following an experimental human challenge.

Robinson RE. et al, (2026), Front Microbiol, 17

Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.

Hamilton DO. et al, (2026), PLoS Negl Trop Dis, 20

Correction: Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Mamede I. et al, (2026), Front Immunol, 17

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?